白雲山(00874.HK)擬使用1.18億元募集資金通過子公司向甘肅中藥科技增資
格隆匯12月2日丨白雲山(00874.HK)公吿,2021年8月2日,公司第八屆董事會第十四次會議、第八屆監事會第十次會議審議通過了《關於部分募集資金使用用途變更的議案》,將“大南藥”研發平台建設項目研發投入中的1.18億元變更至甘肅廣藥白雲山中藥科技產業園(一期)項目。2021年9月30日,公司召開2021年第一次臨時股東大會,審議通過該議案。
為保證甘肅廣藥白雲山中藥科技產業園(一期)項目的順利實施,公司於2021年12月2日召開第八屆董事會第十七次會議、第八屆監事會第十三次會議,審議通過了《關於使用募集資金向全資子公司增資暨全資子公司向全資孫公司增資的議案》,同意公司使用原募投項目“大南藥”研發平台建設項目研發投入募集資金中的1.184億元通過全資子公司採芝林藥業向募投項目實施主體、本公司全資孫公司甘肅中藥科技公司增資,用於甘肅廣藥白雲山中藥科技產業園(一期)項目建設。
增資完成後,採芝林藥業仍為公司持股100%的全資子公司;甘肅中藥科技公司仍為本公司持股100%的全資孫公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.